Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia

The Dana-Farber Cancer Institute (DFCI) Childhood ALL Consortium Protocol 95-01 was designed to minimize therapy-related morbidity for children with newly diagnosed ALL without compromising efficacy. Patients participated in randomized comparisons of (1) doxorubicin given with or without dexrazoxane...

詳細記述

保存先:
書誌詳細
主要な著者: Moghrabi, Albert, Levy, Donna E., Asselin, Barbara, Barr, Ronald, Clavell, Luis, Hurwitz, Craig, Samson, Yvan, Schorin, Marshall, Dalton, Virginia K., Lipshultz, Steven E., Neuberg, Donna S., Gelber, Richard D., Cohen, Harvey J., Sallan, Stephen E., Silverman, Lewis B.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Hematology 2007
主題:
Clinical Trials and Observations
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC1785142/
https://ncbi.nlm.nih.gov/pubmed/17003366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-06-027714
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料